Patients with multiple CALMs w/wo skinfold freckling and no other typical NF1 associated features (Lisch nodules, bone abnormalities, neurofibromas, optic pathway gliomas). The DNA-based ...

This approval was based on findings from the ReNeu trial (NCT03962543), and in an interview with study author Christopher L. Moertel, MD, he explains how mirdametinib adds to the NF1-associated ...